View in EDS HTML Full Text PDF Full Text

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

Saved in:
Bibliographic Details
Title: HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.
Authors: Sánchez-Bayona R; Hospital Universitario 12 de Octubre, Madrid, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Martínez-Sáez O; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Romero-Romero D; Hospital Universitario 12 de Octubre, Madrid, Spain., Seguí E; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Carcelero E; Pharmacy Department, Hospital Clinic, Barcelona, Spain., Tolosa P; Hospital Universitario 12 de Octubre, Madrid, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain., Soberino J; Breast Cancer Unit, IOB-QuirónSalud, Barcelona, Spain., Alva M; Hospital Universitario 12 de Octubre, Madrid, Spain., Pascual T; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Lema L; Hospital Universitario 12 de Octubre, Madrid, Spain., Garcia-Fructuoso I; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Medicine Department, University of Barcelona, Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Cobos-Fernandez MA; Hospital Universitario 12 de Octubre, Madrid, Spain., Rey M; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Manso L; Hospital Universitario 12 de Octubre, Madrid, Spain., Aguirre A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Madariaga A; Hospital Universitario 12 de Octubre, Madrid, Spain., Sirenko V; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., González-Deza C; Hospital Universitario 12 de Octubre, Madrid, Spain., Blasco P; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Mayhua A; Hospital Universitario 12 de Octubre, Madrid, Spain., Castillo O; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Galván P; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain., Sanfeliu E; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Pathology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Buckingham W; Reveal Genomics, Barcelona, Spain., Marín-Aguilera M; Reveal Genomics, Barcelona, Spain., Paré L; Reveal Genomics, Barcelona, Spain., Villagrasa P; Reveal Genomics, Barcelona, Spain., Perou CM; Reveal Genomics, Barcelona, Spain., Maues J; GRASP, Baltimore, MD, USA., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., Ciruelos E; Hospital Universitario 12 de Octubre, Madrid, Spain.; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Centro Integral Oncológico Clara Campal HM (CIOCC), Madrid, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. alprat@clinic.cat.; Medicine Department, University of Barcelona, Barcelona, Spain. alprat@clinic.cat.; Cancer Institute and Blood Disorders, Hospital Clinic, Barcelona, Spain. alprat@clinic.cat.; Reveal Genomics, Barcelona, Spain. alprat@clinic.cat.
Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Apr 25; Vol. 11 (1), pp. 37. Date of Electronic Publication: 2025 Apr 25.
Publication Type: Journal Article
Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2374-4677
DOI:10.1038/s41523-025-00753-8